October was another busy month in Huntington’s disease (HD) research! We learned more about often-overlooked symptoms, ...

The FDA has accepted uniQure’s application for AMT-130 (now called ifezuntirgene inilparvovec), an experimental gene therapy ...

An experimental treatment for HD developed by Alnylam has shown long-lasting huntingtin lowering after just one dose, with ...

HD researchers developed an AI-powered tool that analyzes a short counting task. Its speech measures reflected clinical scores and HD-related changes over time, suggesting it could be used as a remote ...

For decades, Huntington’s disease (HD) research has focused on what goes wrong inside vulnerable brain cells. But neuronsneuron Brain cells that store and transmit information don’t work alone, they ...

The lines between HD and catatonia may sometimes be blurred. However, recognising that occasionally there can be more than ...

In plain language. Written by scientists. For the global HD community.

In plain language. Written by scientists. An experimental treatment for HD developed by Alnylam has shown long-lasting huntingtin lowering after just one dose, with encouraging early safety data. A ...

This Fall, HDBuzz is proud to launch our “Falling Into Hope” fundraising campaign. Our goal is simple but ambitious: raise $30,000 in the next 8 weeks, by October 28. 2025 will be a landmark year in ...

In an update from uniQure, they report that their experimental gene therapy, AMT-130, has the potential to slow Huntington’s disease progression in key clinical study. HD is caused by a faulty copy of ...

From the clinic, we heard from uniQure about their recent FDA meeting, a stem cell trial dosed its first participant, and Skyhawk shared data on SKY-0515. In the lab, the science of slowing HD at the ...

Day 2 of #HD2026 brought us updates on the mechanics of somatic instability, new ways to track HD in people, AI tools to help drive research forward, and developments in our understanding of the HTT ...